Notes 11-15
- 11 Other investments
- 12 Inventories
- 13 Trade and other receivables
- 14 Cash and cash equivalents
- 15 Interest bearing loans and borrowings
11 OTHER INVESTMENTS
| 2007 $m |
2006 $m |
2005 $m |
|
|---|---|---|---|
| Non-current investments | |||
| Loans and receivables at fair value through profit or loss | – | 37 | 100 |
| Equity securities available for sale | 182 | 82 | 156 |
| 182 | 119 | 256 | |
| Current investments | |||
| Equity securities held for trading | 31 | 26 | 16 |
| Fixed deposits | 60 | 559 | 1,549 |
| Derivative financial instruments | 86 | 72 | 59 |
| 177 | 657 | 1,624 | |
Impairment charges of $18m in respect of available for sale securities are included in other operating income and expense in the income statement (2006 $nil, 2005 $16m included in research and development).
In 2006, the Group completed the acquisition of Cambridge Antibody Technology Group plc, which was previously held as an available for sale investment.
